Vusolimogene Oderparepvec

Phase 3Gene therapy

YYana Najjar

Vusolimogene Oderparepvec is one of 58 biologic programs targeting Advanced Melanoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Advanced MelanomaRecruiting

MetastasisRecruiting

AngiosarcomaRecruiting

Advanced MelanomaPhase 3

Recruiting

MetastasisPhase 1

Recruiting

AngiosarcomaPhase 2

Recruiting

Competition

Competitive Landscape

64 competitors in Metastasis

#DrugCompanyPhaseTrials

Blenoxane

Bristol-Myers Squibb

Approved

1 2

Norvir

Neoral

Lynparza

Tukysa

Taxol

Trexall

Verzenio

Zometa

Gemzar

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Recruiting

Metastasis

NCT06216938

Q4 2029

Phase 2Recruiting

Angiosarcoma

NCT06898970

Q1 2031

Phase 3Recruiting

Advanced Melanoma

NCT06264180

Clinical

Trials by Indication[1]

Metastasis1 trial

RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node Metastasis

Recruiting·YYana Najjar·Phase 1·NCT06216938·25 enrolled

Angiosarcoma1 trial

An Open-Label, Multicenter, Phase 2 Study With Safety Lead-In of Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab in Patients With Angiosarcoma

Recruiting·VVarun Monga, MBBS·Phase 2·NCT06898970·18 enrolled

Advanced Melanoma1 trial

Randomized, Ph3 Clinical Study Comparing Vusolimogene Oderparepvec in Combination With Nivolumab Vs Treatment of Physician's Choice in Patients With Advanced Melanoma That Progressed on Anti-PD-1 and Anti-CTLA-4 Containing Treatment [IGNYTE-3]

Recruiting·RReplimune Inc.·Phase 3·NCT06264180·400 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Vusolimogene Oderparepvec. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Vusolimogene Oderparepvec compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Vusolimogene Oderparepvec. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Yana Najjar company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Gene therapy[2]
Highest Phase: Phase 3[1]
Company: YYana Najjar

Vusolimogene Oderparepvec

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q4 2029

Q1 2031

Trials by Indication[1]

Metastasis1 trial

Angiosarcoma1 trial

Advanced Melanoma1 trial

References

Drug Info

Quick Facts

Related News